We came across one bullish thesis at Bruker Corporation on r/valueinvesting by TheDynamicMolecule. In this article, we will summarize the bulls’ thesis on BRKR. Bruker Corporation stock traded at $48.39 on January 16. BRKR’s trailing and forward P/E were 66.98 and 21.83, respectively, according to Yahoo Finance.

Bruker Corporation has established itself as a leading player in advanced scientific instrumentation, with strong positions in mass spectrometry, NMR, optical systems, metrology and space biology. The company’s deep technology offerings enable cutting-edge research in genomics, proteomics and transcriptomics, serving as critical tools for other innovators.

Over the past few years, Bruker has expanded aggressively through acquisitions and internal R&D, notably consolidating its dominance in space biology with companies such as NanoString, Canopy, and Bruker spinout Spatial Genomics.

These platforms now lead the market in spatial genomics, proteomics and transcriptomics, competing with or surpassing players such as 10x Genomics, Illumina, PAC Bio and Akoya. Spatial biology itself is an enduring growth area, as existing sequencing and epigenomics techniques cannot fully capture the functional complexity of proteins and cells, ensuring continued demand for Bruker’s tools.

Despite this strong technology and market positioning, Bruker has faced headwinds from macro factors, notably cuts in non-profit and US R&D funding from 2025 onwards, which have impacted revenue visibility. The company has also seen high stock volatility, with prices ranging between $38 and $64 over the past year, largely driven by news of external financing rather than operating performance.

Operationally, however, Bruker remains financially sound, with resilient earnings even amid revenue fluctuations due to cost management and continued product demand. Institutional investors such as BlackRock, Vanguard and T. Rowe Price are holding positions, indicating confidence in long-term fundamentals.

Given its market leadership, strong product ecosystem, and resilient profitability, Bruker appears materially undervalued at a market cap of $7.35 billion, with a realistic valuation closer to $15 billion. Steady demand for space biology and other core technologies positions the company for substantial upside, making it an attractive long-term holding despite short-term volatility.

Previously, we covered a bullish thesis on Bruker Corporation (BRKR) by FckYouMoney in May 2025, which highlighted the stock’s decline despite growing revenue, strong free cash flow, and the potential for an upside toward $80 if margins improve. BRKR’s stock price has appreciated approximately 18.80% since our coverage as the thesis developed. TheDynamicMolecule shares a similar bullish view, but emphasizes Bruker’s leadership in space biology and advanced scientific instrumentation.